Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quemliclustat + Enfortumab Vedotin + Pembrolizumab in Advanced Urothelial Carcinoma
NCT07667335Phase 2Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Oct 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of quemliclustat in urothelial carcinoma (UC), sponsored by Fred Hutchinson Cancer Center. Started Oct 2026; status: recruiting.
02
Drugs
quemliclustat
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07667335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667335.